Press Releases
Page 9 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Mabwell Subsidiary T-mab Passes Jordan GMP Inspection for Denosumab Biosimilars
Mabwell's T-mab subsidiary receives GMP compliance approval from Jordan FDA for two denosumab biosimilars, marking regulatory milestone for bone treatments.
Quality Executive Partners Partners with Vi'eNnI to Expand Virtuosi Training Platform in India's Pharmaceutical Market
QxP announces exclusive partnership with Vi'eNnI to scale Virtuosi workforce development platform across India's growing pharmaceutical sector.
SynSmart and Amporin Partner to Develop Small Molecule Therapeutics for Degenerative Diseases
SynSmart Rasayan Research and Amporin Pharmaceuticals announce collaboration to develop breakthrough small molecule treatments for fatal degenerative diseases.
Alamar Biosciences NASDAQ IPO: Precision Proteomics Company Debuts at $1.5B Valuation
Alamar Biosciences (NASDAQ:ALMR) successfully listed on NASDAQ at $17 per share, opening at $22.6 with $1.5B market cap in precision proteomics breakthrough.
ACT Genomics Expands Cancer Genomic Testing Panel to 101 Genes with 7-Day Turnaround Time
ACT Genomics upgrades ACTDrug genomic testing to 101-gene panel with 7-day results for advanced cancer patients, enhancing precision medicine capabilities.
Zai Lab's ZL-1503 Bispecific Antibody Shows Promise for Rapid Itch Relief in Atopic Diseases
Zai Lab's ZL-1503, an IL-13/IL-31Rα bispecific antibody, demonstrates rapid itch relief and inflammation reduction in preclinical atopic disease studies.
Zai Lab's ZL-1503 Bispecific Antibody Shows Rapid Itch Relief in Atopic Disease Preclinical Data
Zai Lab presents promising preclinical data for ZL-1503, an IL-13/IL-31Rα bispecific antibody targeting rapid itch relief and inflammation reduction in atopic diseases.
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Corporation unveiled three innovative cancer treatment programs at AACR 2026, featuring next-generation ADC and TCE technologies for oncology patients.
Antengene Presents Next-Generation ADC and AnTenGager TCE Programs at AACR 2026
Antengene showcases three novel oncology programs at AACR 2026, featuring next-generation ADC technology and AnTenGager T-cell engagers for cancer treatment.
Atara Biotherapeutics Class Action Lawsuit Filed: ATRA Stockholders May Recover Investment Losses from May 2024-January 2026
Robbins LLP announces class action lawsuit for Atara Biotherapeutics (ATRA) investors who purchased securities between May 20, 2024 and January 9, 2026.
Sanyou AI-STAL 2.0 Reduces Antibody Discovery Time from Months to 14 Days in Drug Development Breakthrough
Sanyou's AI-STAL 2.0 platform revolutionizes drug discovery by reducing antibody development timelines from months to just 14 days, transforming pharmaceutical R&D.
Gene Expression Analysis Market Reaches $5.93 Billion by 2031, Driving Drug Discovery Innovation
Gene expression analysis market projected to grow from $4.23B in 2026 to $5.93B by 2031 at 7.0% CAGR, led by drug discovery applications.